Life Science Investing CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting
Life Science Investing CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025